Clinicopathological Characteristics, Treatment, and Prognosis of Rarely Primary Epididymal Adenocarcinoma: A Review and Update

Table 4

Summary of immunohistochemical marker expression status in primary epididymal adenocarcinoma.

Marker	Primary epididymal adenocarcinoma
	Positive/total cases	Negative/total cases
CEA	2/5	3/5
PSA	0/5	5/5
CK7	2/4	2/4
EMA	4/4	0/4
AFP	0/3	3/3
Calretinin	0/3	3/3
CD10	3/3	0/3
Vimentin	1/3	2/3
CA19-9	1/2	1/2
CAIX	2/2	0/2
CD30	0/2	2/2
CDX2	0/2	2/2
CK	2/2	0/2
CK20	1/2	1/2
C-KIT	0/2	2/2
HBME1	1/2	1/2
Inhibin	0/2	2/2
Leu-M1	0/2	2/2
PAP	0/2	2/2
PAS	2/2	0/2
PLAP	0/2	2/2
S100	0/2	2/2
TTF-1	0/2	2/2
WT1	0/2	2/2
AMACR	0/1	1/1
B72.3	0/1	1/1
Ber-EP4	0/1	1/1
CA125	0/1	1/1
CAM5.2	1/1	0/1
CK5	0/1	1/1
CK AE1/AE3	1/1	0/1
Glypican	0/1	1/1
GST-α	0/1	1/1
HCG	0/1	1/1
LCA	0/1	1/1
Melan-A	0/1	1/1
Mesothelin	1/1	0/1
P53	1/1	0/1
PAX2	1/1	0/1
PROSAP	0/1	1/1
RCC	0/1	1/1
SALL4	0/1	1/1
Villin	1/1	0/1
Vinculin	1/1	0/1